CNR1 may reverse progesterone-resistance of endometrial cancer through the ERK pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Endometrial cancer (EC) treatment often involves endocrine therapy, but progesterone resistance is a significant challenge.
• The Cancer Genome Atlas (TCGA) database indicates CNR1 expression negatively correlates with overall survival (OS) and relapse-free survival (RFS) in EC.
• Understanding the role of CNR1 in progesterone resistance is crucial for developing effective EC therapies.

Purpose of the Study:

• To investigate the role of CNR1 in progesterone resistance in endometrial cancer.
• To explore the molecular mechanisms underlying CNR1's involvement in progesterone resistance.
• To assess the therapeutic potential of targeting CNR1 for overcoming progesterone resistance in EC.

Main Methods:

• Established progesterone-resistant IshikawaPR cells from Ishikawa cells.
• Assessed CNR1 expression levels using MTT, RT-PCR, Western blot, and immunofluorescence.
• Utilized lentiviral CNR1-knockdown vectors to transfect IshikawaPR cells.
• Evaluated changes in cell proliferation, migration, and progesterone sensitivity via plate cloning, EdU assay, flow cytometry, Transwell, and Scratch assays.
• Investigated in vivo efficacy using subcutaneous xenografts in nude mice.

Main Results:

• CNR1 knockdown in IshikawaPR cells significantly reduced proliferation and migration.
• Knockdown of CNR1 enhanced progesterone sensitivity in EC cells.
• CNR1 knockdown led to the downregulation of ERK and NFκB expression and activation.
• In vivo studies corroborated the in vitro findings, suggesting therapeutic potential.

Conclusions:

• Targeting CNR1 can potentially reverse progesterone resistance in endometrial cancer.
• CNR1 plays a critical role in regulating cell proliferation, migration, and progesterone sensitivity in EC.
• The findings suggest that CNR1 may coordinate with ERK pathway activation in EC, offering a novel therapeutic target.